This trial (innovaTV-301) led to the full FDA approval for tisotumab in patients with metastatic cervical cancer. This is the first ADC targeting Tissue Factor that I am aware of. The data showed modest survival benefits, but this was more tolerable than traditional second- and third-line chemotherapy.
A nod to our gynecologic oncologists. Minimally invasive surgery was significantly inferior to open radical hysterectomy for early-stage cervical cancer.
This is a Chinese study of neoadjuvant camrelizumab (PD1-MAb) + platinum-based chemo showing impressive effectiveness with an overall response rate (ORR) of 83% and a complete response (CR) of 19%. This drug is being studied in esophageal-SCC with promising reports as well. We will see if this gets studied in a Western population.
In the EORTC-55994 study, neoadjuvant chemotherapy followed by chemoradiation + surgery was not superior to chemoradiation for patients with stage IB2 – IIB cervical cancer. However, the toxicity was acceptable, so for patients with more locally advanced disease, it could be considered. Regardless, the SOC will remain concurrent chemotherapy and radiation for these patients.
FCS Hematology Oncology Review creates a platform for our physician network to observe the most recent articles and studies available in the oncology and hematology world. By sharing these articles we are building our wealth of knowledge of new observations and treatments as they come available.
